Cochrane for Clinicians
Putting Evidence into Practice
Oral H1 Antihistamines as Add-on Therapy to Topical Treatment for Eczema
Am Fam Physician. 2019 Nov 1;100(9):541-542.
Author disclosure: No relevant financial affiliations.
Are oral H1 antihistamines effective add-on therapy to topical treatments for eczema?
In children with eczema, there is no evidence to support the addition of oral H1 antihistamines to standard treatment regimens. In adults, the use of fexofenadine (Allegra), 120 mg per day, improves patient-assessed eczema symptoms compared with placebo (number needed to treat = 11; 95% CI, 5.5 to 255).1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
Eczema (atopic dermatitis) is a chronic inflammatory skin condition resulting in an itchy, red rash that affects roughly 31.6 million people in the United States.2 The disease occurs in 13% of children and 7% of adults,3,4 and significantly affects quality of life. Patients with eczema report that the disease causes embarrassment and frustration and interferes with daily activities, and children report being bullied in school.5,6 Conventional eczema treatment involves topical emollients, corticosteroids, and immunomodulators. However, some patient resources mention oral antihistamines as a possible treatment option.7,8
This Cochrane review included 25 randomized controlled trials with 3,285 participants (1,344 adults and 1,941 children).1 In total, 13 oral H1 antihistamines were studied. Primary outcomes included change in patient-assessed symptoms of eczema and the adverse effect rate reported by participants. Secondary outcomes included change in physician-assessed clinical signs of eczema, change in patient-reported quality of life, and number of eczema flare-ups. The authors reported the effects from specific trials instead of pooling the data because the studies used different oral H1 antihistamines, topical agents (mostly different potency corticosteroids), and durations of treatment.
The reviewers found no evidence demonstrating improvement in primary or secondary outcomes with the use of cetirizine (Zyrtec) or loratadine (Claritin) in children or adults. Reported adverse effects did not differ between treatment and placebo groups. Moderate-quality evidence revealed a small reduction in patient-assessed eczema symptoms (mean difference = –0.25; 95% CI, –0.43 to –0.07; P = .006) with the use of fexofenadine, 120 mg per day, in adults. Acrivastine, azelastine (Astelin), chlorpheniramine, chlorpheniramine maleate, hydroxyzine, ketotifen (Zaditor), and levocetirizine (Xyzal) were not found to be helpful as add-on therapy for eczema.
Topical moisturizers, corticosteroids, and immunomodulators continue to be the main treatments for eczema. The low quality of evidence and lack of standardization among the studies made the pooling of data difficult; nonetheless, the evidence suggests that most oral H1 antihistamines have no role in the treatment of eczema. Neither the 2018 consensus-based European guidelines for the treatment of atopic eczema nor the 2014 American Academy of Dermatology atopic dermatitis guidelines mentions the use of oral H1 antihistamines in this patient population.9,10 They do, however, warn against the use of topical antihistamines. The European guidelines state that there is insufficient evidence to demonstrate the effectiveness of oral H1 antihistamines, and the American Academy of Dermatology does not support their routine use.
The practice recommendations in this activity are available at http://www.cochrane.org/CD012167.
Editor's Note: The numbers needed to treat reported in this Cochrane for Clinicians were calculated by the authors based on raw data provided in the original Cochrane review. Dr. Saguil is a contributing editor for AFP.
The views expressed in this article are the authors' and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. government.
Referencesshow all references
1. Matterne U, Böhmer MM, Weisshaar E, et al. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev. 2019;(1):CD012167....
2. Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82–91.
3. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107–114.
4. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.
5. Anderson RT, Rajagopalan R. Effects of allergic dermatosis on health-related quality of life. Curr Allergy Asthma Rep. 2001;1(4):309–315.
6. National Eczema Association. In your words. 2017. Accessed March 13, 2019. https://nationaleczema.org/in-your-words-survey-series/#Caregiver
7. American Academy of Family Physicians. Eczema and atopic dermatitis. Updated June 8, 2017. Accessed March 13, 2019. https://familydoctor.org/condition/eczema-and-atopic-dermatitis/?adfree=true
8. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Atopic dermatitis. Updated July 2016. Accessed March 13, 2019. https://www.niams.nih.gov/health-topics/atopic-dermatitis#tab-treatment
9. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I [published correction appears in J Eur Acad Dermatol Venereol. 2019;33(7):1436]. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
10. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, assistant medical editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2021
Access the latest issue of American Family Physician